Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2019 Annual Meeting occurring March 13-16, 2019 in Washington, D.C.
Lin Lin, PhD, Principal Scientist at Applied BioMath is presenting the poster "Quantitative Systems Pharmacology Model of Amyloid Beta and Plaque Dynamics in Alzheimer's Disease upon Treatment with Anti-Amyloid Beta Drugs Crenezumab, Solanezumab, and Bapineuzumab" during the pre-conference session "Advancing QSP Toward Predictive Drug Development: From Targets to Treatments" on March 13, 2019 from 8:00a.m. – 5:00p.m. The poster is also being presented during the conference's poster session on Friday, March 15, 2019 from 11:30a.m. – 1:00p.m. This poster features research that supports the grant Applied BioMath was awarded in October 2017 by the National Institute on Aging of the NIH for the development of a systems pharmacology model in Alzheimer's Disease and Dementia.
Daniel Kirouac, PhD, Sr. Principal Scientist at Applied BioMath is chairing the session "Connecting Cell Biology to Patient Populations-Clinical Applications of Multi-Scale Systems Pharmacology" on Friday, March 15, 2019 from 3:45p.m. – 5:45p.m. Dr. Kirouac currently serves as the community chair for ASCPT'S Systems Pharmacology Community.
"We are excited to attend and present our Model-Aided Drug Invention (MADI) approach with the attendees at the ASCPT 2019 Annual Meeting," said John Burke, PhD, Co-Founder, President and CEO, Applied BioMath. "With this year's theme being 'From Molecule to Patient' it's important to highlight how our approach helps our partners de-risk projects, accelerate development of best-in-class therapeutics, and reduce late stage attrition rates; ultimately resulting in making better therapeutics which improve patients' lives."
In addition to the poster presentations and session, Applied BioMath will have a booth throughout the conference. For more information about Applied BioMath's presence at the ASCPT 2019 Annual Meeting, visit https://www.appliedbiomath.com/news-resources/events/ascpt-2019-annual-meeting.
For more information about Applied BioMath's upcoming events, visit www.appliedbiomath.com/news-resources/events.
About Applied BioMath
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.
Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com